Business context and reporting period
This filing is Aquinox Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015—not a filing for Neurogene Inc. The company is a clinical-stage drug developer focused on SHIP1-targeting therapies. Its lead candidate, AQX-1125, was in Phase 2 trials for COPD, bladder pain syndrome/interstitial cystitis (BPS/IC), and atopic dermatitis (AD). All amounts below are U.S. dollars.
Financial results and liquidity
| Metric | Q1 2015 | Q1 2014 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.567 million | $1.880 million |
| General and administrative expense | $1.472 million | $0.735 million |
| Total operating expenses | $6.039 million | $2.615 million |
| Net loss | $6.412 million | $4.228 million |
| Net loss per share, basic and diluted | $0.60 | $1.28 |
| Cash used in operating activities | $6.755 million | $3.803 million |
As of March 31, 2015, cash and cash equivalents were $14.283 million and short-term investments were $20.135 million, for combined liquid resources of $34.418 million. Working capital was approximately $30.050 million; total liabilities were $5.051 million. The company reported no outstanding loan balance; its Silicon Valley Bank loan had been repaid in 2014. A $79,000 warrant derivative liability remained. No revenue or profit margin is applicable because the company had no revenue and reported a net loss. Accumulated deficit was $95.827 million.
Changes versus the prior comparable period
- Operating expenses rose 131% year over year, led by R&D expense, which increased 143% as three Phase 2 programs advanced. G&A expense doubled, reflecting public-company costs, added personnel, consultants, insurance, and travel.
- Net loss increased 52%, while operating cash use increased 78%, primarily reflecting greater clinical-development spending.
- Loss per share improved from $1.28 to $0.60, but weighted-average shares increased substantially—from 3.15 million to 10.71 million—following the 2014 IPO and conversion of preferred shares.
- Q1 2014 results included a $1.884 million charge from extinguishing preferred-stock discount and a $0.914 million gain from derivative-liability remeasurement, as well as loan-repayment costs. These items did not recur in Q1 2015, so reported losses are not directly comparable without considering them.
- Cash and cash equivalents declined $0.623 million during Q1 2015. Maturities of investments provided $6.066 million of investing cash flow; this was principally a shift in investment holdings, not operating cash generation.
Outlook, commentary, and risks
- Management expected significant expenses and operating losses to continue and said existing capital resources were expected to fund operations for at least the next 12 months. It also anticipated needing substantial additional financing in the future; equity financing could dilute shareholders, and debt could impose senior rights or restrictive covenants.
- Management expected R&D spending to increase as AQX-1125 trials progressed. BPS/IC and COPD enrollment was complete, with top-line results expected near mid-2015. AD enrollment was announced complete on May 4, 2015, after quarter-end; top-line data was expected by Q1 2016.
- Material development risks include unproven SHIP1 biology, uncertain Phase 2 efficacy and safety, no established optimal dose, and regulatory uncertainty. The filing notes the FDA had accepted EXACT-PRO for the COPD Phase 2 trial but had not accepted it for pivotal trials; a different endpoint or longer Phase 3 trial could be required.
- Animal toxicology studies showed severe gastrointestinal ulcerations in dogs and ocular-lens effects in some animals; the company cautioned that human implications were uncertain. Mild gastrointestinal effects were the most common reported side effects in completed trials. COPD exacerbations requiring hospitalization occurred in the Flagship trial and were described as expected for the study population.
- Other risks include dependence on contract research organizations and manufacturers (including a single-source API manufacturer), foreign-exchange exposure without hedging, competition, intellectual-property challenges, and the possibility of delays or failure to obtain regulatory approval. The company reported no material legal proceedings, no off-balance-sheet arrangements, and no material changes in contractual commitments from its 2014 Form 10-K.
- Management reported disclosure controls were effective at a reasonable-assurance level and no period change in internal control over financial reporting materially affected, or was reasonably likely to materially affect, those controls. The filing also notes significant deficiencies identified in the prior-year audit and continuing work to meet public-company control requirements.
Important facts for investors to verify
- Confirm the issuer and period: the supplied filing identifies Aquinox Pharmaceuticals, Inc. and Q1 2015, despite the request metadata naming Neurogene Inc.
- Verify subsequent clinical-trial readouts and whether the reported anticipated timing and trial endpoints were achieved.
- Assess the adequacy of the stated 12-month cash runway against the reported quarterly operating cash burn and planned development spending.
- Review later disclosures on AQX-1125 safety, optimal dose, FDA feedback on COPD endpoints, and Phase 3 requirements.
- Track financing needs, potential dilution, manufacturing scale-up and supplier concentration, and remediation of previously identified control deficiencies.